Date: 2011-06-17
Type of information: R&D agreement
Compound: production of two monoclonal therapeutic antibodies
Company: Algenics (France) Novimmune (Switzerland)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Algenics announced a new research collaboration with NovImmune to biomanufacture monoclonal therapeutic antibodies using its proprietary expression platform Algebiosys®. Two fully human therapeutic antibodies have been retained from NovImmune’s current pipeline to be produced in the PTA microalgal cell line. There are numerous benefits to using microalgal expression systems over current technologies such as advantageous N-glycosylation profile, natural cell robustness and lack of animal-derived components, while retaining the use of conventional upstream and downstream processing equipments. This collaboration with NovImmune will validate this new and innovative system for the biomanufacturing of fully human therapeutic monoclonal antibodies. Terms around the collaboration have not been disclosed.
Financial terms:
Latest news:
